Program
clofutriben
Also written as “SPI-62”, “ASP3662” and “SPI-62 dose”.
Its studies are mostly in Polymyalgia Rheumatica · Diabetes Mellitus, Type 2 · Cushing Syndrome · Obesity, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sparrow Pharmaceuticals | 72 open or running | phase 2since Mar 23, 2022 | Mar 23, 2022 | Dec 31, 2027phase 2 · NCT07296484 |
| Astellas Pharma | 20 open or running | phase 2since Feb 21, 2015 | Jul 16, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2014First study: phase 1 study in Pharmacokinetics of ASP3662New to Astellas PharmaAstellas Pharma · NCT02194491 · 18 enrolled · United States
- Feb 21, 2015Phase 2 study in Painful Diabetic Peripheral Neuropathy (PDPN)Astellas Pharma · NCT02372578 · 115 enrolled · United States
- Mar 23, 2022Sparrow Pharmaceuticals's first study: phase 1 study in ObesityNew to Sparrow PharmaceuticalsSparrow Pharmaceuticals · NCT05409027 · 12 enrolled · United States
- Mar 23, 2022Phase 2 study in ACTH Syndrome, EctopicSparrow Pharmaceuticals · NCT05307328 · 26 enrolled · United States, Bulgaria, Romania
- Jun 23, 20222 phase 2 studiesSparrow Pharmaceuticals · NCT05436652, NCT05436639
- Feb 20, 2024Phase 1 study in Polymyalgia RheumaticaSparrow Pharmaceuticals · NCT06281236 · 1 enrolled · Germany
- Nov 6, 2025Phase 1 study in Moderate Renal ImpairmentSparrow Pharmaceuticals · NCT07227922 · 16 planned · United States
- Nov 30, 2025Phase 2 study in Diabetes Mellitus, Type 2Sparrow Pharmaceuticals · NCT07296484 · 1,500 planned · United States
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2Sparrow Pharmaceuticals · NCT07296484
TargetBeta
“An orally bioavailable selective inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1; HSD1; HSD-1), ”NCIt, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07296484Diabetes Mellitus, Type 2 · United States | 2 | Recruiting | Sparrow Pharmaceuticals | Dec 31, 2027 | 1,500 |
| NCT07227922Moderate Renal Impairment · United States | 1 | Recruiting | Sparrow Pharmaceuticals | Apr 30, 2026 | 16 |
| NCT06281236Polymyalgia Rheumatica · Germany | 1 | Terminated | Sparrow Pharmaceuticals | Mar 25, 2025 | 1 |
| NCT05436652Polymyalgia Rheumatica · Germany, Poland | 2 | Completed | Sparrow Pharmaceuticals | Apr 25, 2025 | 66 |
| NCT05436639Acth-Independent Macronodular Adrenal Hyperplasia · United States, Romania, United Kingdom | 2 | Completed | Sparrow Pharmaceuticals | Dec 1, 2024 | 30 |
| NCT05409027Obesity · United States | 1 | Completed | Sparrow Pharmaceuticals | Mar 10, 2022 | 12 |
| NCT05307328ACTH Syndrome, Ectopic · United States, Bulgaria, Romania | 2 | Completed | Sparrow Pharmaceuticals | Aug 1, 2025 | 26 |
| NCT02372578Painful Diabetic Peripheral Neuropathy (PDPN) · United States | 2 | Terminated | Astellas Pharma | May 20, 2016 | 115 |
| NCT02194491Pharmacokinetics of ASP3662 · United States | 1 | Completed | Astellas Pharma | May 2016 | 18 |
How it is read
Names in the registry
- “SPI-62”, 4 entries
- “ASP3662”, 2 entries
- “clofutriben”, 1 entry
- “SPI-62 dose”, 1 entry
- “12mg clofutriben”, 1 entry
Conditions, from the studies’ own filings
- Polymyalgia Rheumatica, 2 studies
- Diabetes Mellitus, Type 2, 1 study
- Cushing Syndrome, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.